Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting

- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency - BEDFORD, Mass., May 03, 2023 --... | May 3, 2023

Related Keywords

Oxford Biomedica ,Albert Seymour ,Cara Mayfield ,Brad Smith ,American Society Of Gene Cell Therapy ,Exchange Commission ,Globenewswire Inc ,Securities Exchange ,Company Contacts ,Nasdaq ,Homology Medicines Inc ,Corporate Communications ,Identify Genomic Sites ,Improved Gene Editing Integration Efficiency ,Cell Therapy ,Annual Meeting ,Chief Executive Officer ,Across Species ,Regimen Used ,Ongoing Clinical Trials ,Nonclinical Support ,Gene Therapy Candidate ,Therapy Candidate ,Metachromatic Leukodystrophy ,Across Clades ,Neutralizing Antibodies ,Homologous Recombination Based Gene ,Homology Directed Strand Cross Over Using ,Homology Medicines ,Securities Act ,Securities Exchange Act ,Annual Report ,Business Officer ,Nc Stock Exchange ,News ,Information ,Press Release ,Reclinical ,Data ,Jets ,Emonstrating ,Potential ,O ,Ith ,Avhscs ,End ,Identify ,Enomic ,Sites ,Mproved ,Gene ,Editing ,Integration ,Efficiency ,Bay ,023 Fixx Us4380831077 ,